FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311422489> ?p ?o ?g. }

• W4311422489 endingPage "867" @default.
• W4311422489 startingPage "841" @default.
• W4311422489 abstract "Background & AimsFibroblast activation protein (FAP) is expressed on activated fibroblast. Its role in fibrosis and desmoplasia is controversial, and data on pharmacological FAP inhibition are lacking. We aimed to better define the role of FAP in liver fibrosis in vivo and in vitro.MethodsFAP expression was analyzed in mice and patients with fibrotic liver diseases of various etiologies. Fibrotic mice received a specific FAP inhibitor (FAPi) at 2 doses orally for 2 weeks during parenchymal fibrosis progression (6 weeks of carbon tetrachloride) and regression (2 weeks off carbon tetrachloride), and with biliary fibrosis (Mdr2−/−). Recombinant FAP was added to (co-)cultures of hepatic stellate cells (HSC), fibroblasts, and macrophages. Fibrosis- and inflammation-related parameters were determined biochemically, by quantitative immunohistochemistry, polymerase chain reaction, and transcriptomics.ResultsFAP+ fibroblasts/HSCs were α-smooth muscle actin (α-SMA)-negative and located at interfaces of fibrotic septa next to macrophages in murine and human livers. In parenchymal fibrosis, FAPi reduced collagen area, liver collagen content, α-SMA+ myofibroblasts, M2-type macrophages, serum alanine transaminase and aspartate aminotransferase, key fibrogenesis-related transcripts, and increased hepatocyte proliferation 10-fold. During regression, FAP was suppressed, and FAPi was ineffective. FAPi less potently inhibited biliary fibrosis. In vitro, FAP small interfering RNA reduced HSC α-SMA expression and collagen production, and FAPi suppressed their activation and proliferation. Compared with untreated macrophages, FAPi regulated macrophage profibrogenic activation and transcriptome, and their conditioned medium attenuated HSC activation, which was increased with addition of recombinant FAP.ConclusionsPharmacological FAP inhibition attenuates inflammation-predominant liver fibrosis. FAP is expressed on subsets of activated fibroblasts/HSC and promotes both macrophage and HSC profibrogenic activity in liver fibrosis. Fibroblast activation protein (FAP) is expressed on activated fibroblast. Its role in fibrosis and desmoplasia is controversial, and data on pharmacological FAP inhibition are lacking. We aimed to better define the role of FAP in liver fibrosis in vivo and in vitro. FAP expression was analyzed in mice and patients with fibrotic liver diseases of various etiologies. Fibrotic mice received a specific FAP inhibitor (FAPi) at 2 doses orally for 2 weeks during parenchymal fibrosis progression (6 weeks of carbon tetrachloride) and regression (2 weeks off carbon tetrachloride), and with biliary fibrosis (Mdr2−/−). Recombinant FAP was added to (co-)cultures of hepatic stellate cells (HSC), fibroblasts, and macrophages. Fibrosis- and inflammation-related parameters were determined biochemically, by quantitative immunohistochemistry, polymerase chain reaction, and transcriptomics. FAP+ fibroblasts/HSCs were α-smooth muscle actin (α-SMA)-negative and located at interfaces of fibrotic septa next to macrophages in murine and human livers. In parenchymal fibrosis, FAPi reduced collagen area, liver collagen content, α-SMA+ myofibroblasts, M2-type macrophages, serum alanine transaminase and aspartate aminotransferase, key fibrogenesis-related transcripts, and increased hepatocyte proliferation 10-fold. During regression, FAP was suppressed, and FAPi was ineffective. FAPi less potently inhibited biliary fibrosis. In vitro, FAP small interfering RNA reduced HSC α-SMA expression and collagen production, and FAPi suppressed their activation and proliferation. Compared with untreated macrophages, FAPi regulated macrophage profibrogenic activation and transcriptome, and their conditioned medium attenuated HSC activation, which was increased with addition of recombinant FAP. Pharmacological FAP inhibition attenuates inflammation-predominant liver fibrosis. FAP is expressed on subsets of activated fibroblasts/HSC and promotes both macrophage and HSC profibrogenic activity in liver fibrosis." @default.
• W4311422489 created "2022-12-26" @default.
• W4311422489 creator A5005647313 @default.
• W4311422489 creator A5008566878 @default.
• W4311422489 creator A5015033283 @default.
• W4311422489 creator A5016240303 @default.
• W4311422489 creator A5022092357 @default.
• W4311422489 creator A5022641610 @default.
• W4311422489 creator A5023246606 @default.
• W4311422489 creator A5036511512 @default.
• W4311422489 creator A5059465335 @default.
• W4311422489 creator A5066330334 @default.
• W4311422489 creator A5088109431 @default.
• W4311422489 date "2023-01-01" @default.
• W4311422489 modified "2023-10-15" @default.
• W4311422489 title "Fibroblast Activation Protein Activates Macrophages and Promotes Parenchymal Liver Inflammation and Fibrosis" @default.
• W4311422489 cites W1545804167 @default.
• W4311422489 cites W1547216586 @default.
• W4311422489 cites W1965834132 @default.
• W4311422489 cites W1969051655 @default.
• W4311422489 cites W1975016799 @default.
• W4311422489 cites W1976937182 @default.
• W4311422489 cites W1980724829 @default.
• W4311422489 cites W1981262534 @default.
• W4311422489 cites W1986998151 @default.
• W4311422489 cites W2018046176 @default.
• W4311422489 cites W2047764904 @default.
• W4311422489 cites W2075290880 @default.
• W4311422489 cites W2077759978 @default.
• W4311422489 cites W2079648100 @default.
• W4311422489 cites W2094470344 @default.
• W4311422489 cites W2122641355 @default.
• W4311422489 cites W2150006350 @default.
• W4311422489 cites W2163962028 @default.
• W4311422489 cites W2256440089 @default.
• W4311422489 cites W2278964323 @default.
• W4311422489 cites W2282926206 @default.
• W4311422489 cites W2400022769 @default.
• W4311422489 cites W2570320388 @default.
• W4311422489 cites W2594491387 @default.
• W4311422489 cites W2690065025 @default.
• W4311422489 cites W2756554481 @default.
• W4311422489 cites W2774304513 @default.
• W4311422489 cites W2790513179 @default.
• W4311422489 cites W2791033272 @default.
• W4311422489 cites W2796699845 @default.
• W4311422489 cites W2893835498 @default.
• W4311422489 cites W2894425317 @default.
• W4311422489 cites W2899389750 @default.
• W4311422489 cites W2899585661 @default.
• W4311422489 cites W2902538813 @default.
• W4311422489 cites W2944564829 @default.
• W4311422489 cites W2952175821 @default.
• W4311422489 cites W2955659826 @default.
• W4311422489 cites W3001420005 @default.
• W4311422489 cites W3007829107 @default.
• W4311422489 cites W3025157658 @default.
• W4311422489 cites W3039317121 @default.
• W4311422489 cites W3044392771 @default.
• W4311422489 cites W3081755994 @default.
• W4311422489 cites W3088941414 @default.
• W4311422489 cites W3095484986 @default.
• W4311422489 cites W3095979138 @default.
• W4311422489 cites W3127821066 @default.
• W4311422489 cites W3134387503 @default.
• W4311422489 cites W3135145632 @default.
• W4311422489 cites W3160673950 @default.
• W4311422489 cites W3204664147 @default.
• W4311422489 cites W4211260107 @default.
• W4311422489 doi "https://doi.org/10.1016/j.jcmgh.2022.12.005" @default.
• W4311422489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36521660" @default.
• W4311422489 hasPublicationYear "2023" @default.
• W4311422489 type Work @default.
• W4311422489 citedByCount "7" @default.
• W4311422489 countsByYear W43114224892023 @default.
• W4311422489 crossrefType "journal-article" @default.
• W4311422489 hasAuthorship W4311422489A5005647313 @default.
• W4311422489 hasAuthorship W4311422489A5008566878 @default.
• W4311422489 hasAuthorship W4311422489A5015033283 @default.
• W4311422489 hasAuthorship W4311422489A5016240303 @default.
• W4311422489 hasAuthorship W4311422489A5022092357 @default.
• W4311422489 hasAuthorship W4311422489A5022641610 @default.
• W4311422489 hasAuthorship W4311422489A5023246606 @default.
• W4311422489 hasAuthorship W4311422489A5036511512 @default.
• W4311422489 hasAuthorship W4311422489A5059465335 @default.
• W4311422489 hasAuthorship W4311422489A5066330334 @default.
• W4311422489 hasAuthorship W4311422489A5088109431 @default.
• W4311422489 hasBestOaLocation W43114224891 @default.
• W4311422489 hasConcept C111798993 @default.
• W4311422489 hasConcept C121608353 @default.
• W4311422489 hasConcept C126322002 @default.
• W4311422489 hasConcept C142724271 @default.
• W4311422489 hasConcept C176891718 @default.
• W4311422489 hasConcept C202751555 @default.
• W4311422489 hasConcept C203014093 @default.
• W4311422489 hasConcept C2776200302 @default.
• W4311422489 hasConcept C2776914184 @default.
• W4311422489 hasConcept C2780381497 @default.

• next